Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis.

[1]  J. Signorovitch,et al.  Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. , 2020, Journal of comparative effectiveness research.

[2]  F. Paul,et al.  Suggestions for improving the design of clinical trials in multiple sclerosis—results of a systematic analysis of completed phase III trials , 2019, EPMA Journal.

[3]  Jeffrey A. Cohen,et al.  Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial , 2019, The Lancet Neurology.

[4]  Jeffrey A. Cohen,et al.  Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial , 2019, The Lancet Neurology.

[5]  D. Ontaneda,et al.  Diagnosis and Management of Progressive Multiple Sclerosis , 2019, Biomedicines.

[6]  S. Broadley,et al.  The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses , 2019, Front. Neurol..

[7]  F. Paul,et al.  Ozanimod for the treatment of relapsing remitting multiple sclerosis , 2018, Expert opinion on pharmacotherapy.

[8]  J. Valle,et al.  Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison. , 2018, Journal of comparative effectiveness research.

[9]  D. Centonze,et al.  Fingolimod vs dimethyl fumarate in multiple sclerosis , 2018, Neurology.

[10]  A. Ziegler,et al.  Treatment choices and neuropsychological symptoms of a large cohort of early MS , 2018, Neurology: Neuroimmunology & Neuroinflammation.

[11]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[12]  Sofia Dias,et al.  Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  H. Gross,et al.  Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey , 2017, Neuropsychiatric disease and treatment.

[14]  R. Fox,et al.  Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis , 2017, Current medical research and opinion.

[15]  J. Chataway,et al.  Multiple sclerosis, a treatable disease  , 2016, Clinical medicine.

[16]  Gavin Giovannoni,et al.  Brain health: time matters in multiple sclerosis. , 2016, Multiple sclerosis and related disorders.

[17]  F. Lublin,et al.  Novel Agents for Relapsing Forms of Multiple Sclerosis. , 2016, Annual review of medicine.

[18]  M. Comabella,et al.  Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis , 2016, CNS Drugs.

[19]  T. Kalincik.  Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review , 2015, Neuroepidemiology.

[20]  Gavin Giovannoni,et al.  No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis , 2014, Advances in Therapy.

[21]  A. Finkelsztejn.  Multiple Sclerosis: Overview of Disease-Modifying Agents , 2014, Perspectives in medicinal chemistry.

[22]  Jeffrey A. Cohen,et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.

[23]  L. Kappos,et al.  Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial , 2014, Multiple sclerosis.

[24]  M. Hutchinson,et al.  Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison , 2014, Current medical research and opinion.

[25]  L. Kappos,et al.  Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.

[26]  M. Tullman,et al.  Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. , 2013, The American journal of managed care.

[27]  Mei Lu,et al.  Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  Mei Lu,et al.  Comparative effectiveness research using matching‐adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention‐deficit/hyperactivity disorder and comorbid oppositional defiant disorder , 2012, Pharmacoepidemiology and drug safety.

[29]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[30]  Christian Confavreux,et al.  Randomized trial of oral teriflunomide for relapsing multiple sclerosis. , 2011, The New England journal of medicine.

[31]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[32]  C. Polman,et al.  Assessing disability progression with the Multiple Sclerosis Functional Composite , 2009, Multiple sclerosis.

[33]  R. Scheyer,et al.  A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses , 2006, Neurology.

[34]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[35]  F. Lublin,et al.  Effect of relapses on development of residual deficit in multiple sclerosis , 2003, Neurology.

[36]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[37]  K. Aronson.  Quality of Life Among Persons with Multiple Sclerosis and their Caregivers , 1997, Neurology.

[38]  Eric Q. Wu,et al.  Comparative Effectiveness Without Head-to-Head Trials , 2012, PharmacoEconomics.